Taiwan based TWi Biotechnology has been granted patent in Korea for it diabetes drug, AC-201, from the Korean Intellectual Property Office. The patent includes AC-201 or its pharmaceutically acceptable salts or active metabolites for treatment of both type I and type II diabetes. The patent also covers the methods of treatment using AC-201 for type II diabetes, and provides a protection period up to year 2030. This patent adds to TWi Biotechnology's broad intellectual property portfolio for AC-201. This patent has been allowed in US, Mexico, New Zealand, China and Russia.
The Biotechnician-TWi Biotechnology Inc recently acquired a major patent for its famous drug AC-201 from South Korea. What is your team’s future plans in South Korea after acquiring this important patent?
Calvin C. Chen-We want to eventually collaborate with a regional or Korean pharmaceutical company to develop and commercialize our products for the Korean market.
The Biotechnician-Why is South Korea a key market for your team?
Calvin C. Chen –South Korea we believe is a large market and has a relative independent regulatory system. The country also has good record in making approval ahead of other major regulatory agencies compared to many other Asian states.
The Biotechnician-What is the future of developing AC-201 and getting it out to the market?
Calvin C. Chen-Because AC-201 has the potential to be used for multiple indications, we are considering to seek for co-development partners in the near future to get in into the market faster.
The Biotechnician-Do you think that AC-201 will be the way to treat type II diabetes in the future?
Calvin C. Chen-Yes, because it has a unique mode of action that targets the inflammation part of diabetes while showing good efficacy in reducing HbA1c.